Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM02

Impact of Drug Repository Program in a Rural Oncology Clinic

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Adverse Events, Oncology Pharmacy Programs

Presenter: Stephanie Evangelisti, PharmD, MS, BCOP, Oncology Pharmacy Director, Grand Valley Oncology (Community Hospital), CO

Co-Authors: Brenda Butchko, CPhT, Grand Valley Oncology, CO; Alisha Reynolds, Grand Valley Oncology, CO

Background: Rules adopted in 2008, but repealed in 2020, by the Colorado State Legislature and State Board of Pharmacy, allowed patients with cancer or the patient’s family member to donate previously dispensed oral cancer medications to pharmacies for the purpose of redispensing to patients who cannot afford their prescribed medications.1 Because 16% of the population in Mesa County, Colorado, live below the poverty line, Grand Valley Oncology opted to participate in this drug recycling program to increase access and minimize waste of expensive oral cancer medications.

Objective: To determine the impact of the Cancer Drug Repository Program in terms of increased patient access to oral medications used in the treatment of cancer, including side-effect management, and decreased pharmaceutical waste.

Methods: Donations of noncontrolled medications received between January 1, 2019, and December 31, 2019, were reviewed by a pharmacist to ensure that the following conditions were met: used in the treatment of cancer, including side-effect management; stored in the original, unopened, sealed, and tamper-evident packaging; properly stored at room temperature; and within expiration date. If a patient undergoing cancer treatment was uninsured, underinsured, or demonstrated significant financial need, then a financial counselor would meet with the patient to review applicable medication access programs, such as the Cancer Drug Repository Program, manufacturer assistance programs, and grants. The patient, if eligible to participate, was required to acknowledge receipt of donated medication.

Results: A total of 34 medications were donated to the Cancer Drug Repository Program between January 1, 2019, and December 31, 2019. The total average sales price (ASP) for these donated medications was $569,592. Six patients were deemed eligible to participate in the program based on financial need and availability of donated medication; 12 prescriptions (ASP, $240,854) of the available 34 were dispensed to these individuals at the time of repeal.

Conclusion: Financial toxicity can be a significant burden to individuals diagnosed with cancer and their families. Although assistance was limited based on the availability of donated medications, the practice still promoted improved access to oral cancer medications. Resources, such as the drug recycling program, should be utilized to help increase patient access to, and minimize waste of, expensive oral cancer medications. This project was undertaken as a Quality Improvement Initiative at Colorado West Healthcare System (Grand Valley Oncology) and, as such, was not formally supervised by an Institutional Review Board.

  1. Colorado Department of Regulatory Agencies; State Board of Pharmacy. Rule 3.00.80 Return or Exchange of Drugs, Prescriptions, Medical Devices, and Medical Supplies for Dispensing or Donation. HB15-1039, General Assembly of the State of Colorado, 2015.
Related Items
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD, YoungYoon Ham, PharmD, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in Review Article, Adverse Events, Antibiotics, Drug Resistance
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, COVID-19
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, Oncology Pharmacy Protocols
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Infusion Issues
Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Chemotherapy, Oncology Pharmacy Programs
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma, Vaccinations
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.